THPO and Thrombocytopenia: Compared to the non-EMD group, there was a higher incidence of any grade (95% vs 74%, p = 0.0006) and grade ≥3 thrombocytopenia (62% vs 38%, p = 0.0087) in the EMD group which translated to a higher rate of thrombopoietin agonist use (38% vs 15%; p = 0.02) for the EMD group.